BIOMAT Database Logo BIOMAT Database Logo

l-Theanine prevents carbon tetrachloride-induced liver fibrosis via inhibition of nuclear factor κB and down-regulation of transforming growth factor β and connective tissue growth factor. 2016

J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Department of Pharmacology, Cinvestav-IPN Apartado, D.F. México.

Here we evaluated the ability of L-theanine in preventing experimental hepatic cirrhosis and investigated the roles of nuclear factor-κB (NF-κB) activation as well as transforming growth factor β (TGF-β) and connective tissue growth factor (CTGF) regulation. Experimental hepatic cirrhosis was established by the administration of carbon tetrachloride (CCl4) to rats (0.4 g/kg, intraperitoneally, three times per week, for 8 weeks), and at the same time, adding L-theanine (8.0 mg/kg) to the drinking water. Rats had ad libitum access to water and food throughout the treatment period. CCl4 treatment promoted NF-κB activation and increased the expression of both TGF-β and CTGF. CCl4 increased the serum activities of alanine aminotransferase and γ-glutamyl transpeptidase and the degree of lipid peroxidation, and it also induced a decrease in the glutathione and glutathione disulfide ratio. L-Theanine prevented increased expression of NF-κB and down-regulated the pro-inflammatory (interleukin (IL)-1β and IL-6) and profibrotic (TGF-β and CTGF) cytokines. Furthermore, the levels of messenger RNA encoding these proteins decreased in agreement with the expression levels. L-Theanine promoted the expression of the anti-inflammatory cytokine IL-10 and the fibrolytic enzyme metalloproteinase-13. Liver hydroxyproline contents and histopathological analysis demonstrated the anti-fibrotic effect of l-theanine. In conclusion, L-theanine prevents CCl4-induced experimental hepatic cirrhosis in rats by blocking the main pro-inflammatory and pro-fibrogenic signals.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D002252 Carbon Tetrachloride Poisoning Poisoning that results from ingestion, injection, inhalation, or skin absorption of CARBON TETRACHLORIDE. CCl4 Poisoning,Poisoning, CCl4,Poisoning, Carbon Tetrachloride,CCl4 Poisonings,Carbon Tetrachloride Poisonings,Poisonings, Carbon Tetrachloride
D005971 Glutamates Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. Glutamic Acid Derivatives,Glutamic Acids,Glutaminic Acids
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic
D015227 Lipid Peroxidation Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. Lipid Peroxidations,Peroxidation, Lipid,Peroxidations, Lipid
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats.
July 2006, The journal of gene medicine,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Transforming growth factor-β-independent role of connective tissue growth factor in the development of liver fibrosis.
October 2014, The American journal of pathology,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase.
August 2007, World journal of gastroenterology,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP.
October 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion.
January 2016, Gut and liver,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
N-acetylcysteine prevents carbon tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-beta and oxidative stress.
August 2009, European journal of gastroenterology & hepatology,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
NF-κB inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells.
July 2014, Experimental and therapeutic medicine,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride.
July 2013, Phytotherapy research : PTR,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Melatonin attenuates carbon tetrachloride-induced liver fibrosis via inhibition of necroptosis.
September 2015, Translational research : the journal of laboratory and clinical medicine,
J E Pérez-Vargas, and N Zarco, and P Vergara, and M Shibayama, and J Segovia, and V Tsutsumi, and P Muriel
Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis.
January 2004, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,
Copied contents to your clipboard!